Value Creation Plan Growth-Area Sales Targets and Plan Revisions
First written in FY2024. 1 of 3 entries say "Softened", first in FY2024. Latest entry: FY2026.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2026AdvancedAnnual report
「During the current fiscal year, we have been steadily implementing various measures under the 3 priority initiatives set out in the Medium-Term Management Plan 2027, and overall progress has been solid and in line with the plan.」
The Group described progress on structural reform, stronger portfolio management, and a greater focus on the diagnostics and life sciences fields as “smooth,” and outlined initiatives including organizational restructuring, working capital improvements, ROIC management, optimization of production sites, and new product launches. - FY2025ReframedAnnual report
「In November 2024, the Group formulated the Medium-Term Management Plan 2027 and established a new vision, “To become a leader that shapes the future of healthcare through sophisticated technologies,” as the vision it aims to achieve by 2030.」
The Group shifted from the previous Value Creation Plan's ¥86 billion 2025 sales target for the growth areas to a planning framework centered on its 2030 vision and Medium-Term Management Plan 2027. - FY2024SoftenedAnnual report
「Revenue in the growth areas (advanced therapy development solutions, digital health solutions, personalized testing, and diagnostic solutions): ¥86 billion by 2025 (VCP: ¥41 billion)」
The Value Creation Plan set a target of ¥86 billion in revenue from 3 growth areas by 2025. At the same time, it stated that the Group was considering revising the plan in light of recent performance trends.